Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. - Wikidata - wikimedia - TriplyDB

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q34975404

about

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis Rituximab for Rheumatoid Arthritis.Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.Rituximab for the treatment of rheumatoid arthritis: an update.An update on the management of hepatitis C virus-related arthritis.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report.Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.Cost-effectiveness analysis of two rituximab retreatment regimens for longstanding rheumatoid arthritis.Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.Response to Dr Bredemeier's letter.Kinetic changes of regulatory B10 cells in collagen-induced arthritis could be regulated by cytokines IFN-γ and TGF-β1.Monitoring B-cell repopulation after depletion therapy in neurologic patients.Q56958599

P2860

Q26852081-D3D9FEC9-EF97-45C1-9BFF-5EF3690200B4 Q28080246-F30E7A32-7D20-444E-85E4-914426754A01 Q30250242-B75E6524-E695-417F-926D-C07290FE7B69 Q31046441-B114BD4F-4FE7-4397-BF51-B8D52767C7F7 Q35662575-1BE14917-8B40-4BF6-8343-E2F1D1A5F08B Q35809549-0DCC327E-0F5E-4217-83D3-9179883071AB Q37444678-2B7D709E-617B-447C-BB4C-866C8DF589F8 Q38242116-BD91A101-AA18-4309-AA48-80E5D62A8BD4 Q38540353-A43DF0BF-05C8-4576-B332-E92A914B1A3B Q38690022-621B97C9-FBFA-4541-931A-66C192CED311 Q38751251-3519451E-68D9-454F-B0C2-7F521762319D Q39692977-19D1AC34-FC92-41B4-92C8-385DEC5F08B4 Q39830050-7E9FFF0E-B610-4A51-A1D9-9892B712BD2B Q40127724-F4262444-3C01-47D7-AA5D-42E73E10159B Q41571651-52DDA605-FF9B-4819-A152-3FC68790F576 Q41593204-FDA37BA8-67E4-4EE3-9FA2-684298111066 Q42639790-010B77F3-9DAC-4A4D-A406-6DD2AB30CE60 Q45765360-9BFF2583-6FEE-4A22-9CA8-5D51CDDF060A Q50014741-8E31D088-539B-4868-9F7D-121903AF9039 Q52839527-9DA77AD7-BE83-4A6F-8D7B-0CAFE2958FBF Q52840072-4CA96462-7509-446B-B841-12670932FB95 Q53452331-EAB19E1A-0AE8-4D2F-B0E2-E3A48801D0E2 Q55283551-9F94BD9A-A8BE-434A-8F77-47CCC0E35683 Q56958599-D80F2534-FFE9-4EE7-9C32-FAF1D4281E88

P2860

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q34975404

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@ast

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@en

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@nl

type

label

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@ast

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@en

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@nl

prefLabel

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@ast

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@en

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@nl

P1433

Q34975404-FC1CD51D-504E-4E6F-A831-798B60BD4C65

P1476

Q34975404-63E57776-C6A9-40AC-91A1-D1225FF9BD68

P2093

Q34975404-AF36AF62-9B49-415D-9F1A-2256679A414B

Q34975404-B98485BD-E88C-4BC8-B126-082A661E8413

P2860

Q34975404-1405C2A6-B180-4CBE-B589-E6EE1DDC5A6D

Q34975404-1EBD54C2-9588-4AC0-8C1B-7333BEE10E6F

Q34975404-1EF76914-9DB8-49F5-A704-5684AC1702FC

Q34975404-48AF497B-5425-4A37-BF65-89824827D638

Q34975404-4FFB410D-59A2-4C42-9139-C74A678508CC

Q34975404-523B65BF-B772-403D-8606-A3D85EC1B096

Q34975404-5515F1F2-1C2A-4B56-A459-524C372BDF4B

Q34975404-5A24427E-09EF-4702-8F1D-1889D792B375

Q34975404-6016DA23-F0C5-4F69-9197-8887C12DB892

Q34975404-69C1B07C-7AD5-4FDE-ABA4-0D1673D7124B

P304

Q34975404-BBF1DEE7-EB10-4255-8706-0BBB50FF0044

P31

Q34975404-85489f60-451b-444c-b3af-a05826f5420b

Q34975404-E0A70DF5-E387-42AD-84AD-21BA842D2C26

P356

Q34975404-E6A1EBAE-DE8C-4AD3-8DB5-B614A194D048

P433

Q34975404-BFE1398C-B14C-496C-8C9F-E3D8AD71A650

P478

Q34975404-C9CED02E-4CDE-42E8-B3E1-D12731FD551A

P50

Q34975404-7810E860-333D-460A-9021-D0DB4DEEC48B

P577

Q34975404-C3BD756B-3807-4E34-BA5F-CFE0D45C2FA5

P5875

Q34975404-70CE7CEA-7835-4BE8-BBEE-88314A47AD73

P698

Q34975404-25847B07-9B48-46D9-890A-839A08422296

P921

Q34975404-08F8DE48-E182-4FD6-B839-D06DBA5F92BC

P356

P1433

Arthritis Care and Research

P1476

Low- versus high-dose rituxima ...... atic review and meta-analysis.

@en

P2093

Cláudia M Rocha

http://www.w3.org/2001/XMLSchema#string

Fernando K de Oliveira

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

A systematic review identifies a lack of standardization in methods for handling missing variance data.

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

P304

228-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.22116

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Markus Bredemeier

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256189843

http://www.w3.org/2001/XMLSchema#string

P698

23983134

http://www.w3.org/2001/XMLSchema#string

P921